Loading...
•
Mar 31
Avadel Q1 2025 Earnings Report
Avadel Pharmaceuticals reported strong first quarter 2025 financial results, driven by significant growth in LUMRYZ sales and patient additions, and raised its full-year 2025 guidance.
Key Takeaways
Avadel Pharmaceuticals plc announced robust financial results for the first quarter ended March 31, 2025, with net product revenue from LUMRYZ sales reaching $52.5 million, a 93% increase year-over-year. The company added 300 patients on LUMRYZ during the quarter, bringing the total to 2,800. Following a favorable Federal Circuit decision, Avadel is now able to pursue FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) and other indications. The company also raised its full-year 2025 guidance for net product revenue and cash flow.
Net product revenue from LUMRYZ sales increased by 93% to $52.5 million in Q1 2025 compared to Q1 2024.
The number of patients on LUMRYZ reached 2,800 as of March 31, 2025, a 100% year-over-year increase and 300 new patients added in the quarter.
Avadel raised its full-year 2025 guidance, expecting net product revenue of $255 - $265 million and cash flow of $30 - $40 million.
A favorable Federal Circuit ruling allows Avadel to pursue FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) and other indications.
Avadel
Avadel
Avadel Revenue by Segment
Revenue by Segment
LUMRYZ Net Product Revenue
CapyFin.com Forward Guidance
Avadel Pharmaceuticals raised its full-year 2025 guidance, expecting net product revenue between $255 million and $265 million and cash flow between $30 million and $40 million, driven by an anticipated 3,400 to 3,600 patients on LUMRYZ by year-end.
Positive Outlook
- Increased full-year 2025 net product revenue guidance to $255 - $265 million.
- Increased full-year 2025 cash flow guidance to $30 - $40 million.
- Anticipated 3,400 - 3,600 patients on LUMRYZ by year-end 2025.
- On track to complete enrollment in pivotal Phase 3 REVITALYZ™ study for LUMRYZ in IH by the end of 2025.
- Favorable Federal Circuit decision allows pursuit of FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) and additional indications.